河北治疗羊癫疯病的价格(青岛治疗羊癫疯病大概要花几万) (今日更新中)

WASHINGTON, Aug. 12 (Xinhua) -- NASA announced Friday the creation of a new directorate that will focus on both the International Space Station operations and human exploration beyond low earth orbit.The Human Exploration and Operations Mission Directorate combines the Space Operations and Exploration Systems mission directorates. While the transition and personnel assignments will take several weeks to finalize, the directorate already is supporting space station operations. It also will manage commercial crew and cargo developmental programs; construction of the Orion Multipurpose Crew Vehicle, a spacecraft designed to travel beyond low Earth orbit; development of a new heavy lift rocket, known as the Space Launch System; and other programs within the directorates."America is opening a bold new chapter in human space exploration," NASA Administrator Charles Bolden said in a statement. "By combining the resources of Space Operations and Exploration Systems, and creating the Human Exploration and Operations Mission Directorate, we are recommitting ourselves to American leadership in space for years to come."Associate Administrator Bill Gerstenmaier will head the new organization. He previously served as the associate administrator for Space Operations.

WASHINGTON, June 14 (Xinhua) -- Short sleep duration may contribute to the development or worsening of hyperactivity and inattention during early childhood, suggests a research abstract that was presented Tuesday at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.Results show that less sleep in preschool-age children significantly predicted worse parent-reported hyperactivity and inattention at kindergarten. The sample consisted of approximately 6,860 children, and analyses controlled for gender, ethnicity and family income."Children who were reported to sleep less in preschool were rated by their parents as more hyperactive and less attentive compared to their peers at kindergarten," said lead author Erika Gaylor, senior researcher for SRI International, an independent, nonprofit research institute in Menlo Park, California. "These findings suggest that some children who are not getting adequate sleep may be at risk for developing behavioral problems manifested by hyperactivity, impulsivity, and problems sitting still and paying attention." According to the authors, attention-deficit/hyperactivity disorder (ADHD) is not generally diagnosed until the school-age years. However, the onset of developmentally inappropriate inattention, hyperactivity and impulsivity is often much younger. Sleep problems, particularly difficulty falling asleep and staying asleep, are frequently reported in children and adolescents with ADHD. However, the direction of causation, if any, has been difficult to determine. Longitudinal studies may provide a window into the direction of this complex relationship.Last year at SLEEP 2010, Gaylor reported that having a regular bedtime was the most consistent predictor of positive developmental outcomes at four years of age. Having an earlier bedtime also was predictive of higher scores for most developmental measures.

BEIJING, Sept. 26 (Xinhua) -- Nobel laureates on Monday cast doubt on a European experiment that purportedly demonstrated the ability of neutrinos to move faster than the speed of light.They made the remarks in Beijing prior to a forum for Nobel laureates."I'm willing to bet money that it's not correct," said Professor George Smoot III, winner of the 2006 Nobel Prize in Physics and a professor at University of California, Berkeley, referring to an experiment result claiming that particles apparently travel faster than light.The experiment reported an anomaly in the flight time of neutrinos, or electrically neutral subatomic particles, from the European Center for Nuclear Research (CERN) in Switzerland to a laboratory located 730 kilometers away in Italy.Particles were clocked transmitting at a speed of 300,006 kilometers per second, about 60 nanoseconds faster than the speed of light.Smoot said that the claims "did not make sense" and should be verified by other scientists first."There are many distortions in physics. You have to have a very high standard to see if something is truly correct," he said.The unverified findings were published on Sept. 22 in the scientific journal Nature. European researchers working in a team called OPERA (Oscillation Project with Emulsion-Racking Apparatus) projected masses of neutrinos from CERN and then collected the particles using a massive detector in Gran Sasso, south of Rome.Other scientists, as well as the OPERA team themselves, have voiced doubts regarding the experiment's results.The findings, CERN claims, could pose far-reaching potential consequences once verified.If correct, the results would bring Einstein's theory of special relativity into question. Under this theory, a physical object cannot travel faster than the speed of light in a vacuum."If really it is right, we have to rethink everything we know," said Chris Llewellyn Smith, former director of CERN.Smith claimed the unprecedented discovery was too exceptional to find proof."If somebody makes a very exceptional claim, then very exceptional proof would need to come from another experiment, saying the same thing. But we don't have the other thing," Smith said.Carlos Rubbia, a Nobel Laureate who won the prize for physics in 1984, is in charge of a team of more than 100 scientists at CERN."What it is pretending to find, in my view, is unbelievably surprising," Rubbia said."Frankly, I have the feeling that this is still a very experimental consideration," Rubbia said.He also believes that revealing the findings to the public was a mistake as it remained an experimental process and no conclusion could be drawn without the results of another experiment.Despite the possibility of verification, Einstein's special theory of relativity will remain valid."I will be very, very surprised that, at last, Einstein will not be the winner," Rubbia said.To achieve a breakthrough, Rubbia has urged for more joint cooperation on verifying the test results. International cooperation on this issue "is a must.""It requires coordination from all nations," said Rubbia.The 2011 Nobel Laureates Beijing Forum will be held from Sept. 28 to 30 under a theme of "innovation and development."

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

来源：资阳报